title: Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
abstract: We present a 57-year-old Caucasian man with hepatocellular carcinoma (HCC) twice achieving complete remission with reduced dose sorafenib. His initial diagnosis of HCC rapidly improved with sorafenib and he achieved a complete biochemical and radiographic response within 7 months. Remission lasted only 5 months but we noted that the timing of his relapse was immediately after he incidentally discontinued clopidogrel. It was restarted and within 5 months of restarting clopidogrel he once again achieved complete remission. The course of his remission was followed and temporal association of sorafenib remission with use of clopidogrel was observed.
authors.affiliation: Section of Hematology Oncology, Veteran Affairs Medical Center, Pittsburgh, Pennsylvania, USA.
authors.forename: Jocelyn L
authors.initials: JL
authors.lastname: Tan-Shalaby
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000188:drug therapy*; D000077144:Clopidogrel; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D040262:Receptors, Vascular Endothelial Growth Factor; D012074:Remission Induction; D000077157:Sorafenib; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D010975:Platelet Aggregation Inhibitors; D009536:Niacinamide; D000077157:Sorafenib; D000077144:Clopidogrel; D040262:Receptors, Vascular Endothelial Growth Factor; D013988:Ticlopidine